SYK and neoplasm: Diffuse glioma with Sub1 exhibited a worse prognosis, an immunosuppressive tumor microenvironment, significantly higher expression of immune checkpoint genes, and distinct mutation characteristics (Figure 9), which suggested diffuse glioma with Sub1 is more likely to benefit from blocking SYK alone or in combination with other immune checkpoint inhibitors.